Himal L.

Himal L. is a seasoned clinical development leader with extensive experience in gene therapy and vaccine research. Currently serving as Vice President and Head of Clinical Development Organization at bluebird bio since January 2021, Himal L. oversees a team that has achieved three gene therapy approvals and manages clinical development operations, post-marketing studies, and translational medicine. Prior roles at bluebird bio include leading the Clinical Research and Development for Severe Genetic Diseases, where Himal L. successfully navigated three BLA approvals and submissions. Previous experience includes executive roles at Sarepta Therapeutics and Pfizer, where Himal L. managed global gene therapy programs and vaccine studies, respectively. Additionally, early career accomplishments include leading clinical research projects at GlaxoSmithKline and serving as an assistant professor at Saint Louis University School of Medicine, focusing on vaccine clinical research and collaboration with national health organizations.